Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy Meeting Abstract

  

Authors:	Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; Jhaveri, K.; Latif, A.; Modi, S.; Troso-Sandoval, T.; Ulaner, G.; Jochelson, M.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C.
Abstract Title:	Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
Meeting Title:	41st European Society for Medical Oncology Congress (ESMO)
Journal Title:	Annals of Oncology
Volume:	27
Issue:	Suppl. 6
Meeting Dates:	2016 Oct 7-11
Meeting Location:	Copenhagen, Denmark
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2016-10-01
Start Page:	vi84
Language:	English
ACCESSION:	WOS:000393912500269
DOI:	10.1093/annonc/mdw365.49
PROVIDER:	wos
Notes:	Meeting Abstract: 270P -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/109021